The induction of chromosome aberrations, sister chromatid exchanges (SCEs), and the formation of DNA adducts was studied in hepatocytes of F344 rats exposed in vivo to safrole. Hepatocytes were isolated 24 h after a single dose of safrole or five repeated doses (once a day) by gastric intubation and allowed to proliferate in Williams' medium E supplemented with epidermal growth factor. Cells were fixed after 48 h in culture. Safrole-DNA adducts were detected by a nuclease P1-enhanced 32 P-post-labeling assay in isolated hepatocytes from the rats. While a single dose was not sufficient to induce detectable levels of chromosome aberrations at the time of assay, five repeated doses induced these changes with a maximum frequency of 13.4%, compared with the control value of 1.8%. Both a single dose and five repeated doses induced significant SCEs, to a maximum frequency of 0.81 SCEs per chromosome, while the control value was 0.59 SCEs per chromosome. Two major and two minor DNA adducts were detected after treatment with either a single dose or five repeated doses. The maximum amount of total DNA adducts was 89.8 DNA adducts/10 7 nucleotides. These results show that safrole is a genotoxic carcinogen in the rat liver in vivo and suggest that the cytogenetic effects of this compound may result from covalent DNA modification in the rat liver. This in vivo cytogenetic assay should provide a useful means of evaluation of the genotoxicity of hepatocarcinogens.
Introduction
Safrole (1-allyl-3,4-methylenedioxybenzene) is a natural plant constituent found in the essential oils of sassafras, sweet basil and cinnamon (1, 2) , and has been described as a weak hepatocarcinogen in both mice and rats (3) (4) (5) . Safrole is metabolically activated to electrophilic intermediates that bind to cellular DNA, and the DNA binding properties of these metabolites are closely related to the induction of hepatic tumors (6) (7) (8) . With respect to its genotoxic effects, safrole showed negative results in the Ames Salmonella mutation assay (9) , but positive results in various mammalian cell genotoxic assays, such as chromosomal aberrations, sister chromatid exchanges (SCEs*), DNA damage and gene mutation (10) (11) (12) (13) . Despite its ability to induce genotoxicity in these in vitro test systems, safrole has failed to show in vivo genotoxicity in a mouse bone-marrow micronucleus assay *Abbreviations: SCEs, sister chromatid exchanges; EGF, epidermal growth factor; DMN, dimethylnitrosamine; PEI, polyethylenimine; 2AAF, 2-acetylaminofluorene; IQ, 2-amino-3-methylimidazo [4,5-f] quinoline. (14) , in an in vivo rat liver unscheduled DNA synthesis (UDS) assay (15) , in a mouse dominant lethal assay (16) , or in a mouse sperm-head abnormality assay (17) .
It is generally believed that the covalent binding of chemicals or their reactive metabolites to DNA is a key event in the initiation of carcinogenesis and that some genetic changes are a prerequisite to cancer initiation (18) (19) (20) . Although the generation of safrole-DNA adducts is well defined, the role of these adducts in genetic changes in vivo remains unclear. Our laboratory has recently developed an in vivo cytogenetic assay to study the induction of chromosome aberrations and SCEs in the rat liver by hepatocarcinogens, using a combination of treatment of rats with test chemicals in vivo, and culture of their hepatocytes with epidermal growth factor (EGF) as a mitogen treatment in vitro (21, 22) . This assay has the advantage of being simple and allows the assessment of cytogenetic effects in animals under normal conditions without partial hepatectomy or mitogen treatment in vivo.
The current study was undertaken to investigate the in vivo genotoxicity of safrole using our established cytogenetic assay and to evaluate the role of safrole-DNA adduct formation on genetic changes in the liver in these rats.
Materials and methods

Animals and treatments
Male Fischer rats (F344/Du Crj) were purchased from Charles River Japan Inc., Kanagawa. They were housed in stainless steel cages in an animal room with a 12 h light/dark cycle at 22-24°C and 50-60% relative humidity. Food (MF, Oriental Yeast Co. Ltd, Tokyo) and water were available ad libitum throughout the experiment. After 2 weeks of acclimatization, animals of 7-8 weeks old (159-229 g) were randomly divided into dose groups of 3-5 rats and then treated with safrole (Cas registry No. 94-59-7, Aldrich Chemical Co., Inc., Milwaukee, WI) at a single dose of 1, 10, 100, 250 and 500 mg/kg body wt or multiple doses (once a day for 5 days) of 62.5, 125 and 250 mg/ kg body wt by gastric intubation. Animals were killed 24 h after the last dose. The dosing volume of safrole in corn oil was 0.2 ml/100 g body wt. Control animals received the same volume of corn oil.
Isolation and culture of hepatocytes
At 24 h after the final administration of chemicals in vivo, the liver was perfused in situ by the two-step collagenase perfusion technique described elsewhere (23, 24) . The isolated hepatocytes were plated at 1ϫ10 6 viable cells per collagen-coated 55-cm 2 dish (Iwaki glass Co. Ltd, Tokyo) in 10 ml of Williams' medium E (Flow Laboratories Inc., Irvine, CA) supplemented with 10% fetal bovine serum, 10 mM HEPES, 0.1 IU/ml insulin (Sigma Chemical Co., St Louis, MO), 2.5 µg/ml amphotericin B, and 0.1 mg/ml kanamycin. Cultures were incubated for 48 h at 37°C under 5% CO 2 in humidified air. The medium was renewed after 2 and 24 h by further addition of 50 ng/ml of EGF (Collaborative Research Inc., Bedford, MA) for the chromosome aberration assay, and of 50 ng/ml of EGF and 2 µg/ml 5-bromo-2Ј-deoxyuridine (Sigma Chemical Co.) for the SCEs assay in the dark. The remaining hepatocytes were stored at -80°C for assay of DNA adducts.
Cytogenetic assays
To harvest the metaphase cells, 0.04 µg/ml colcemid was added 3 h prior to termination of the cultures. The medium was then replaced with 0.05% collagenase (type IV, Sigma Chemical Co.) dissolved in phosphate buffered saline and the detached cells were collected by centrifugation. The cells were incubated in hypotonic solution (0.075 M KCl) for 15 min at 37°C and then fixed in methanol-acetic acid solution (3:1). The final cell suspension was dropped onto slides and allowed to dry. For the chromosome aberration assay the preparations were stained with 5% Giemsa solution. For the SCEs assay, the cells were stained with 0.01 mg/ml Hoechst 33258 solution for 20 min, mounted with a coverglass in McIlvaine's buffer solution at pH 8.25 and exposed to 10-watt black light lamps (FL10BL-B, Matsushita Electronics Co., Osaka) at a distance of 1 cm for 10 min at 37°C. The coverglass was then removed and the cells were stained with 5% Giemsa solution.
In the chromosome aberration assay, 100 well-spread metaphase cells per animal were examined for aberrations and 2000 nuclei per animal were examined to determine the frequency of mitosis. The aberrations were classified as gaps, chromatid and chromosome breaks, chromatid and chromosome exchanges, and others. A complete discontinuity of less than the width of a chromatid was scored as a gap. SCEs were scored in 25 second-division metaphase cells per animal and the frequency of SCEs per chromosome was recorded.
DNA adduct assay
The presence of adducts in DNA isolated from rat hepatocytes was determined with a nuclease P1-enhanced 32 P-post-labeling assay (25) . DNA was isolated by means of phenol extraction and alcohol precipitation (26) . The concentration of DNA was determined spectrophotometrically (1 mg/ml of DNA ϭ 20 absorbance units at 260 nm). An aliquot of 12 µg of DNA was digested with micrococcal nuclease (Worthington Biochemical Co. Ltd, Freehold, NJ) and spleen phosphodiesterase (Worthington) for 3 h at 37°C. To 10 µl of the digested nucleotides (1 µg DNA/µl) was added 7 µl of a reaction solution containing 2 µl nuclease P1 (4 µg/ml) (Yamasa Shoyu Co., Ltd, Choshi), 2 µl 0.3 mM ZnCl 2 , and 3 µl 0.25 M sodium acetate pH 5.0 for the digestion of DNA with nuclease P1. After incubation at 37°C for 1 h, 3 µl of 0.5 M Tris base was added to adjust the pH to 9.5, and the whole mixture was evaporated to dryness. The dried precipitate was re-dissolved in 10 µl water. For 32 P-labeling, to 10 µl of the nuclease P1 digested nucleotides was added 5 µl of a labeling solution containing: 1.5 µl reaction buffer (100 mM dithiothreitol, 100 mM MgCl 2 , 10 mM spermidine, 300 mM Tris-HCl, pH 9.5), 1 µl carrier-free [γ-32 P]ATP (100 µCi/µl) (ICN Biomedicals Inc., Costa Mesa, CA), 0.5 µl polynucleotide kinase (10 U/µl) (Pharmacia LKB Biotechnology, Uppsala, Sweden) and 1.5 µl water. The 32 P-labeled mixture was incubated at 37°C for 1 h. 32 P-Labeled DNA adducts were mapped by a combination of reversedphase and polyethylenimine (PEI)-cellulose TLC, essentially as described for alkenylbenzene-DNA adducts (27) . All of the 32 P-labeled mixture (10 µg DNA) was applied to a reversed-phase TLC plate (Whatman International Ltd, Maidstone, England) and the plate was developed overnight in 0.4 M ammonium formate, pH 6.0, to remove 32 P-labeled unmodified nucleotides and retain 32 P-labeled DNA adducts at the origin of the chromatogram. The origin containing the retained DNA adducts was transferred in situ to a PEIcellulose TLC (Macherey-Nagel, Dueren, Germany), which was subsequently soaked in water. The transferred 32 P-labeled DNA adducts were then resolved by two-dimensional anion exchange chromatography. This step involved separation on PEI-cellulose TLC plates with the following: (i) a solution of 1.8 M lithium formate, 4.25 M urea, pH 3.5 from bottom to top; (ii) 0.36 M LiCl, 0.22 M Tris-HCl, 3.8 M urea, pH 8.0 from left to right; and (iii) 1.7 M sodium phosphate, pH 6.0 from left to right onto a 3-cm wick.
To examine total nucleotides, 2 µl of the digested nucleotides (1 µg DNA/ µl) was further diluted 1/1000 with water. A 5-µl aliquot (5 ng DNA) was then mixed with 2.5 µl of the labeling solution used for the 32 P-labeling. After incubation at 37°C for 1 h, 2.5 µl potato apyrase (10 units/ml) (Sigma Chemical Co.) was added to the 32 P-labeled nucleotides and the incubation was continued for 45 min. The 32 P-labeled nucleotides were then diluted to 250 µl with water. A 5-µl (0.1 ng DNA) sample of the diluted solution was resolved by PEI-cellulose TLC and the plate was developed with 0.5 M LiCl to the top. DNA adducts were detected by screen-intensified autoradiogram. The spots on the PEI-cellulose TLC plates were cut out and the radioactivities were measured by liquid scintillation counting. DNA adduct levels were calculated as below. Since DNA adducts were evaluated from 10 µg DNA and total nucleotides were evaluated from 0.1 ng DNA, the dilution factor was 10 5 .
Statistical analysis
Results are shown as means for individual rats at each dose. Each point and horizontal line in Figures 1 and 2 is the value for individual rats and the means at each dose, respectively. The statistical significance of differences in chromosome aberrations was analyzed by the Wilcoxon rank sum test. The frequency of SCEs per chromosome, and the body wt gain of animals were statistically analyzed by Student's t-test for equal variance or Aspin-Welch's t-test for unequal variance after analysis of variance by Bartlett's test. The levels of statistical significance were set at P Ͻ 0.05 and P Ͻ 0.01.
Results
Rats were given a single oral dose of 1-500 mg safrole/kg body wt or five repeated doses of 62.5-250 mg safrole/kg body wt. No mortality was observed in the rats after either regimen. The mean body wt gain of rats after five repeated doses of safrole at doses of 62.5, 125 and 250 mg/kg body wt was 17, 15 and 9 g respectively, while that of control rats was 16 g. The values at 250 mg/kg body wt were significantly lower than in the control (P Ͻ 0.01). Mitotic inhibition was observed after both a single dose and five repeated doses of safrole. The frequency of mitosis with safrole by a single dose and five repeated doses was 2.4-1.5% and 2.4-0.8% respectively, while that in controls was 3.2-2.6%. As shown in Figure 1 , a single dose of safrole at doses of 100-500 mg/kg body wt did not induce chromosome aberrations, but five repeated doses dose-dependently increased aberrant cells in the liver. The values for cells with aberrations excluding gaps after five repeated doses of 125 and 250 mg/ kg body wt were significantly different from the control value (P Ͻ 0.05). Chromosome aberrations were observed in 13.4% of the metaphase cells after five repeated doses of safrole at 250 mg/kg body wt, while the control value was 1.8%. Table I shows a summary of the type and number of chromosome aberrations and the frequency of mitosis for individual rats after five repeated doses of safrole. The aberrations induced were mainly chromatid breaks and chromatid exchanges, such as tri-and quadri-radial aberrations.
The dose-dependent induction of SCEs in the liver after a single dose of safrole at doses of 10-500 mg/kg body wt is shown in Figure 2A . The values were significantly different from the control value at doses of 100 (P Ͻ 0.05), 250 and 500 mg/kg body wt (P Ͻ 0.01). A maximum frequency of 0.81 SCEs per chromosome was detected after a single dose of safrole at 500 mg/kg body wt, while the control value was 0.59 SCEs per chromosome. In Figure 2B , five repeated doses of safrole induced a high plateau level of up to 0.86 SCEs per chromosome, compared with the control value of 0.66 SCEs per chromosome. These values were significantly different from the control value at doses of 62.5 (P Ͻ 0.05) and 125 mg/kg body wt (P Ͻ 0.01). However, second-division metaphases could not be analyzed after five repeated doses of 143 safrole at dose of 250 mg/kg body wt because these metaphase cells were in poor condition (Ͻ25 cells) due to severe cytotoxic damage.
Identification and counting of DNA adducts detected in the liver DNA of rats after a single dose of safrole at doses of 1, 10 and 100 mg/kg body wt, and of control rats are shown in Figure 3 . Two major DNA adducts (adducts 1 and 2) were visible on the autoradiograms of the liver DNA isolated from the rats treated with 10 mg/kg body wt ( Figure 3C ) and two minor DNA adducts (adducts 3 and 4) were additionally observed on those with 100 mg/kg body wt ( Figure 3D ) and also with doses of 250 and 500 mg/kg body wt (data not shown), while no adducts were detected in control rats and in rats treated with 1 mg safrole/kg body wt ( Figure 3A and B). Table II shows the level of each DNA adduct and total DNA adducts observed in rats after a single dose or five repeated doses of safrole. The dose-dependent formation of DNA adducts was observed in the liver after both a single dose and five repeated doses of safrole. The maximum amount of total DNA adducts by a single dose and five repeated doses was 72.0 and 89.8 DNA adducts/10 7 nucleotides respectively. After a single dose of 500 mg/kg body wt, adducts 1, 2, 3 and 4 accounted for 45, 47, 5 and 3% of the total DNA adducts respectively, while they accounted for 71, 18, 8 and 3% of the total DNA adducts after five repeated doses of 250 mg/kg body wt.
Discussion
The cytogenetic effects of safrole were studied in the hepatocytes of rats treated with a single dose or five repeated doses. Safrole produced a significant increase in chromosome aberrations in the liver with five repeated doses of 125 and 250 mg/kg body wt and in SCEs in the liver with a single dose of 100-500 mg/kg body wt. The genotoxic activities of safrole have been previously reported in some in vitro assays, including chromosome aberrations (10), SCEs (11), DNA damage (12) and gene mutation (13) in various mammalian cells. In contrast, safrole showed no in vivo genotoxicity in a mouse bone-marrow micronucleus assay (14) , in a UDS assay (15) , in a mouse dominant lethal assay (16) , and in a mouse sperm-head abnormality assay (17) . Therefore, these findings led to speculation that the tumors produced by this chemical might be mediated via some disturbance of normal homeostasis in the test animals (i.e. by a non-genotoxic mechanism) (28) . However, the present study has demonstrated for the first time that safrole induced clear genetic changes in rat liver in vivo, which is the target organ of carcinogenicity. The failure of other in vivo genotoxicity assays to detect the genetic effects of safrole may be due to the use of only a single or two doses and/or that non-target organs were examined in these assays. In the liver UDS assay, a single dose should be probably optimal because the sensitivity of the UDS assay has been reported to decrease considerably when multiple doses are administered (29, 30) . Therefore, the present cytogenetic assay may be more useful for the detection of the genetic effects of safrole than the UDS assay.
The dose range of five repeated doses used in the present study was lower than that used in a previous carcinogenicity study (5) , because the daily intake of safrole at a dietary dose of 0.5% in the carcinogenicity study of rats was calculated to be 375 mg/kg body wt/day, taking an average food intake of 15 g/day per 200 g body wt. The present results show that the induction of chromosome aberrations and SCEs may be directly related to the initiation step of safrole carcinogenicity. We previously reported that chromosome aberrations and
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SCEs induced by hepatocarcinogens could be detected after a single dose using the same cytogenetic assay (21, 22) , i.e. dimethylnitrosamine (DMN)-induced cytogenetic damage up to dose of 2.5 mg/kg body wt, 2-acetylaminofluorene (2AAF) up to dose of 6.25 mg/kg body wt, and 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) up to a dose of 12.5 mg/kg body wt. The cytogenetic activity of safrole observed in this study was weaker than that of these other hepatocarcinogens since safrole barely induced SCEs or chromosome aberrations up to a dose of 100 mg/kg body wt or after five repeated doses respectively. The failure to detect in vivo safrole genotoxicity by other assays may be also due to its weak cytogenetic activity. Furthermore, our in vivo genotoxic results suggest that the lower carcinogenic potency of safrole may be associated with its weaker in vivo genotoxicity compared with the other hepatocarcinogens such as DMN, 2AAF and IQ. Although a large number of studies have analyzed safrole-DNA adducts in mice using a 32 P-post-labeling assay (25, 27, (31) (32) (33) , only limited data are available in rats. Reddy and Randerath (25) reported that two DNA adducts were detected in the liver of adult female CD1 mice treated with safrole by the nuclease P1-modified 32 P-post-labeling assay, and that these DNA adducts were identified as N 2 -(transisosafrol-3Ј-yl)2Ј-deoxyguanosine and N 2 -(safrol-1Ј-yl)2Ј-deoxyguanosine. We analyzed DNA adduct formation by the same 32 P-post-labeling assay under the same chromatographic conditions as Reddy and Randerath, and the two major DNA adducts obtained in this study were very similar to theirs, while the identities of the two minor safrole-DNA adducts (adducts 3 and 4) remain unclear. The maximum levels of total safrole-DNA adducts were similar after a single dose and after five repeated doses, although the total dose value of safrole was 2.5-fold higher with five repeated doses than with a single dose. A significant decrease in body wt gain was observed after five repeated doses of 250 mg/kg body wt in this study. Therefore, DNA adduct formation may be associated with saturation or inhibition of metabolic enzymes involved in safrole hepatotoxicity at the high dose. The sum ratio of the adducts 1 and 2 to total DNA adducts accounted for Ͼ87%, with both a single dose and five repeated doses. On the other hand, the ratio of the adduct 1 to total DNA adducts is approximately similar to that of the adduct 2 after a single dose, but it is higher than that of adduct 2 after five repeated doses. These results indicate that adduct 1 may disappear more slowly than adduct 2 and tend to accumulate with repeated doses, and that the persistence of each DNA adduct may be related to rate of removal of adducts from DNA by different repair processes. The results of the present study may provide a better understanding of the relative estimation of DNA adduct levels. However, absolute DNA adduct levels may not be clear because the 32 P-post-labeling assay does not always show complete recovery of all carcinogen-DNA adducts because of either incomplete DNA digestion, or that an adduct is unstable as a mononucleotide or is a poor substrate for polynucleotide kinase and nuclease P1. An association between carcinogen-DNA adduct levels and in vivo genotoxicity has been reported. Ross et al. (34) found a correlation between DNA adduct levels and SCEs in rats treated with benzo[a]pyrene. Similar relationships were shown between DNA adduct levels and chromosome aberrations in mice exposed to benzidine (35) , micronuclei in rats exposed to N-hydroxy-2-acetylaminofluorene (36) , and mutations in transgenic mice exposed to heterocyclic amines (37) . These findings support the hypothesis that carcinogen-DNA adducts may be responsible for the induction of genotoxic events. Our results demonstrate that DNA adduct levels are more sensitive 145 indicators of safrole's early genetic damage than SCEs or chromosome aberrations. The correlation coefficient for total DNA adducts and SCEs after a single dose of 10-500 mg/kg body wt, or chromosome aberrations after five repeated doses of 62.5-250 mg/kg body wt, was 0.82 (P Ͻ 0.0004 by Fisher's r to z) and 0.61 (P Ͻ 0.085 by Fisher's r to z), respectively. These results suggest that DNA adducts may be more closely related to SCEs than chromosome aberrations. Since five repeated administrations of safrole were required to induce chromosome aberrations, the successive lesions caused by formation and repair of DNA adducts may be an important factor in determining the appearance of this biological response.
Carcinogenesis is a multi-step process consisting of at least initiation, promotion and progression. Initiation involves alteration of DNA, which leads to somatic mutations and triggers carcinogenesis. Although a DNA-damage may not necessarily cause tumor initiation, circumstantial evidence connects these two events. We examined two markers of cytogenetic effects, chromosome aberrations and SCEs, as correlates of tumor-initiating activity and demonstrated that safrole is capable of inducing chromosome aberrations and SCEs in the rat liver in vivo. Therefore, this initiating-activity may play an important role in safrole carcinogenesis. The present cytogenetic assay, using a combination of treatment of rats with test chemicals in vivo and culture of their hepatocytes with EGF as mitogen treatment in vitro, should be useful not only for the determination of genotoxicity of weak hepatocarcinogens such as safrole, but also for the understanding of underlying mechanisms of carcinogenesis.
